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Abstract
Every day, the questions about Cannabis sativa ability to cause chemical dependence are 
closed with the considerable increase in the demand for treatment of addicts to this plant. 
Most drug addicts submitted to treatment have difficulty in achieving and maintaining 
abstinence from Cannabis due to the appearance of symptoms as irritability, anxiety, 
desire to consume marijuana, decreased quality and quantity of sleep, and change in 
appetite, weight loss, and physical discomfort, besides emotional and behavioral symp-
toms. The neurobiological basis for the withdrawal syndrome, that is, withdrawal of 
Cannabis, was established after the discovery of the endogenous cannabinoid system, 
identification of CB1 and CB2 cannabinoid receptors, and demonstrations of precipitated 
removal with antagonists of these receptors. The chapter discusses the main studies cur-
rently conducted for the treatment of withdrawal syndrome based on bioligands that act 
directly on the CB1 cannabinoid receptor.
Keywords: receptor cannabinoid CB1, withdrawal syndrome, Cannabis sativa,  
drugs computer aided
1. Introduction
Cannabis sativa, commonly known as marijuana, is the illicit drug most consumed in many 
countries [1]. The form of Cannabis abuse is predominantly smoked, although it can be found 
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in paste form called hashish, mixed with crack, or as skunk, which is a polymorphic form 
of marijuana [2] cultivated in special appearance and 7–25 times stronger than common 
marijuana causing greater psychotropic effects, as well as adverse effects such as triggering 
of schizophrenia [3].
Studies have found moderate evidence that there is a link between Cannabis use and in rela-
tion to the development of dependence and substance abuse such as alcohol and tobacco 
among other illicit drugs [4], and after a long discussion about the relevance of recent Cannabis 
withdrawal syndrome, this condition was added to the fifth version of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-5) [5]. This syndrome appears within 24 h after 
cessation of Cannabis use, reaches a peak in about days 2–6, and can last from 1 or 2 weeks. 
It affects 55–89% of regular Cannabis users. The Cannabis withdrawal syndrome is clinically 
defined by irritability, anger, nervousness, anxiety, sleep difficulties, decreased appetite or 
weight loss, restlessness, and mood depression, in addition to various physical symptoms 
such as abdominal pain, tremor, or sweating [6–8].
The evidence of Cannabis withdrawal syndrome is based on behavioral observations in animal 
studies [9], clinical observation of patients [10], or epidemiological surveys [11, 12]. However, 
the biological correlates of this phenomenon remain obscure, challenging the validity of the syn-
drome. This lack of knowledge is partly explained by the interindividual variability of delta 9-tet-
rahydrocannabinol (THC) metabolism [13] and the complexity of plasma-tissue exchanges [14].
In the last decades, many studies have been dedicated to discover and understand the diverse 
effects of cannabinoids on the organism whether therapeutic (with the relief of chronic pains 
and muscle spasms related to multiple sclerosis) [15, 16] or derived from the psychoactivity of 
C. sativa, originating the dependence and consequently the withdrawal syndrome [17]. These 
symptoms include physical discomforts such as headaches and stomach psychological symp-
toms accompanied by irritability, anxiety, sleep disturbances, decreased appetite/weight 
loss, restlessness, or depressed mood [18]. The chapter discusses the main studies currently 
conducted for the treatment of Cannabis withdrawal syndrome, that is, molecules which have 
their activity associated with some kind of interaction by structural complementarity beside 
the CB1 cannabinoid receptor.
2. Physiology
2.1. Cannabinoid receptor type 1 (CB1)
After the use of Cannabis, THC interacts with the CB1 cannabinoid receptor, inducing con-
formational changes in this receptor, the interaction with the residue of amino acid TRP356 
and its surroundings being the activation trigger for the signaling [19]. Also, the binding site 
of the CB1 receptor comprises the amino acid residues Phenylalanine 174 (PHE174), Leucine 
193 (LEU193), and Serine 383 (SER383) (Figure 1) that must be in contact or proximity to the 
preferred THC docking position [20].
The morphological differences between CB1 and CB2 cannabinoid receptors indicate that 
most cannabinoid compounds interact differently in both receptors [21], and the location of 
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CB1 receptors in the central nervous system is directly associated with the behavioral effects 
produced by cannabinoids [22, 23]. CB1 gene polymorphisms have been observed and their 
importance is still unknown, but it is suggested that they are linked to increased susceptibility 
to C. sativa dependence and neuropsychiatric disorders [24].
CB1 cannabinoid receptors are present in areas associated with motor control, emotional 
response, learning, memory, goal-oriented behaviors, energy homeostasis, and higher 
cognitive functions, among others [25]. In peripheral organs and tissues, CB1 receptors are 
expressed in low density and have potential implication to regulate inflammation and auto-
immune diseases [26]. Unlike the standard of others neuroreceptor systems, levels of CB1 
receptors in rats are increased in the transition from adolescence to adult age, a fact that sug-
gests the propensity to search for cannabinoid compounds at this stage of life [27].
The CB1 receptor is a subfamily member of the G protein-coupled receptors (GPCRs) [28] and 
is predominantly present in the presynaptic terminal, although small amounts are present in 
peripheral nerves and its function seems to modulate the release of neurotransmitters such as 
dopamine, noradrenaline, glutamate, and serotonin in the synaptic cleft [29].
The inhibition of adenylate cyclase by psychoactive cannabinoids in more densely populated 
regions of CB1 receptors was initially identified in N18TG2 neuroblastoma cells and thereaf-
ter in many other preparations [30]. This inhibition causes modulation of intracellular cAMP 
concentration, thereby regulating protein kinase A (PKA) phosphorylation, fact that may 
result in large changes on cellular activity, such as regulation of K+ channels undergoing PKA 
action in hippocampus [31].
Mitogen-activated protein kinases (MAP kinases) are important signal transduction enzymes 
involved in cell regulation to physiological functions of gene expression control, pro-
liferation, and programmed cell death (apoptosis) [32]. Studies confirm a positive connec-
tion of CB1 receptors with MAP kinase, so that, in vivo, acute administration of Δ9-THC 
and CB1 cannabinoid receptor agonists (CP-55940, WIN 55,212-2, anandamide (AEA), and 
2-O-arachidonoylglycerol (2-AG)) stimulates the MAP kinase of guinea pigs. Synaptic plas-
ticity is considered as the capacity of rearrangement by the neural networks, constitutes 
an important mechanism to recover or adapt in case of injury, and provides the basis for 
most models of learning, memory, and development in neural circuits [33]. Brain-derived 
Figure 1. Amino acid residues present at the cannabinoid receptor binding site CB1.
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neurotrophic factor (BDNF) and Krox-24 gene have been recognized for their importance in 
synaptic plasticity and are prevented by the activation of MAP kinase [34], including studies 
that indicate that cannabinoid receptors alter this physiological process and may favor the 
induction of long-term depolarization (LTD) [35].
The voltage-dependent ion channels, mainly K+ and Ca2+, are modulated by CB1 receptors, 
suggesting that the release of gamma-aminobutyric acid (GABA), a neurotransmitter respon-
sible for CNS inhibition, is mediated by the opening of these channels [36], thus influencing 
cognitive processes such as learning and memory [37].
Cerebral cortex neurons expressing the G-protein coupled receptors, called CCK receptors, 
are responsible for the release of the neuropeptide cholecystokinin (CCK) [38], whose action 
on the hypothalamus produces the sensation of satiety, and also express the CB1 receptors 
[39]. Activation of CB1 receptors also activates CCK receptors, thus inhibiting the release of 
CCK [40] and negatively influencing satiety [41].
Rich areas in CB1 receptors reveal a high expression of N-methyl d-aspartate (NMDA) 
receptors, a class of receptors involved in glutamate neurotransmission and therefore 
important in movement control and memory formation [42]. Cannabinoid substances have 
shown dual effects on NMDA receptor activity, influencing memory acquisition and learn-
ing mechanisms [43].
2.2. Cannabinoid receptor type 2 (CB2)
The main and most well-known location of CB2 receptors on human beings is in nonneuronal 
tissues, mainly in the immune system and hematopoietic cells. The exclusively peripheral 
location of the CB2 receptors was already questioned when, in 2006, their existence was con-
firmed in the nervous system, principally in neuronal, glial, and endothelial cells in the brain, 
although in lower proportions than the CB1 receptors [44]. As CB2 receptors has an important 
role in neuroinflammatory responses, neurodegenerative diseases such as multiple sclerosis, 
amyotrophic lateral sclerosis, and Alzheimer’s disease become the subject of pharmaceutical 
studies in this regard [45], where the concentration of these receptors seems to be increased in 
specific brain regions related to these pathologies [46].
As with CB1 receptors, CB2 receptors are also coupled to G protein although their action 
seems to be part of a general protection system since its activation has no association with 
psychoactive effects. Agonist molecules of these receptors are being tested in neuropsychiat-
ric, cardiovascular, and hepatic pathologies [47].
3. Chemical dependence and withdrawal syndrome
THC is a partial agonist of CB1 and CB2 receptors, although it is the interaction with CB1 
receptors that is responsible for the psychoactive effects of C. sativa [40, 41]. CB1 receptors are 
found at high densities in the ventral tegmental area, nucleus accumbens, prefrontal cortex, 
hippocampus, amygdala, and cerebellum, whereas CB2 receptors are primarily located in 
immune cells [24, 41].
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THC, as well as other CB1 receptor agonists, has inhibitory effects on the release of GABA and 
glutamate. Excitatory effects on dopamine (DA) are also evident, leading to an increase in the 
level of extracellular DA [42].
The chemical dependence on C. sativa develops in about 10% of the people who experience the 
plant, being more common and on higher levels of use at an early age [48]. Withdrawal syn-
drome was recognized and added to DSM-5 in 2014, mainly due to the increase with the num-
ber of treatment episodes to chronic users of Cannabis in the last years [49]. These treatments 
involve psychosocial approaches, but only 20% of patients achieve definitive abstinence [50], 
manifesting a clear need to develop effective treatments for this pathology.
Studies using positron emission tomography revealed a significantly lower availability of 
CB1 receptors between Cannabis smokers and nonsmokers, in which the level of downregu-
lation correlated with the time of Cannabis use [46]. Interestingly, after a 30-day abstinence 
period, there was an increase in CB1 receptor availability to levels comparable to healthy 
controls [6, 51].
For the diagnosis of C. sativa withdrawal, it is necessary to have criteria such as (1) the devel-
opment in specific syndrome of the substance due to cessation or reduction in use; (2) the 
syndrome causes clinically significant distress or impairment in social, occupational, or other 
important areas of functioning; and (3) the symptoms are not due to a general medical condi-
tion and are not better accounted for by another mental disorder [52].
Following the recognition by the ICD-10 (International Statistical Classification of Diseases 
and Related Health Problems) system of Cannabis withdrawal, the demand for treatment of 
Cannabis abuse has grown in several countries and a large proportion of adults and adoles-
cents who participate in the outpatient treatments have difficulty in achieving and maintain-
ing Cannabis withdrawal [53].
3.1. Symptoms of withdrawal syndrome
Experimental studies on Cannabis withdrawal in humans began in the 1970s and showed mod-
erate withdrawal symptoms (such as transient nervousness) following cessation of marijuana 
use and more robust symptoms (restlessness, sleep problems, poor appetite, and disorienta-
tion). In the 1980s, new withdrawal symptoms were reported as decreased appetite/weight 
loss, hostility, irritability, mild nausea, lack of cooperation, restlessness, sleep EEG changes 
(increased REM sleep), and sleep/insomnia difficulties. These symptoms started within 5–6 h 
of the last dose and decreased by 96 h with a reduction in weight and sleep. Changes in EEG 
(i.e., increase in REM) are also observed [54, 55].
More recent studies have demonstrated Cannabis withdrawal syndrome associated with sig-
nificantly increased outcomes of anxiety, depression, and irritability; decrease in sleep quality 
and quantity indices; and decreased food intake [56]. Symptoms such as stomach pain and 
decreased assessments of contentment, friendliness, language, sociability, and energy were 
also reported. Most of the mood symptoms begin within 48 h after cessation and appear to 
peak at day 3 or 4 of the withdrawal phases, and it is interesting to note that studies of oral 
THC use have not reported sleep disturbances during the withdrawal phases [57].
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The symptoms reached the highest levels of aggression on days 3 and 7 of abstinence and 
lasted until day 28, being reported for up to 6 months after cessation of use, showing an effect 
transient. Among chronic and daily users, the appetite decreased after day 9 of abstinence, 
anxiety occurred between days 1 and 11, irritability was greatest on days 1–14, and the mood 
was lower on days 3–9 and was higher on days 1–10. Daily users have higher levels of anxi-
ety, irritability, nervousness, restlessness, tremors, difficulty sleeping, stomach pain, strange 
dreams, excessive sweating, negative mood, physical symptoms, and decreased appetite dur-
ing the abstinence period, suggesting reliable studies of Cannabis abstinence [58, 59].
4. Treatment of withdrawal syndrome
Although there are more than 160 million Cannabis users in the world, no pharmacological 
therapy currently available is considered adequate for the treatment of symptoms caused dur-
ing the withdrawal syndrome. The known effects of withdrawal syndrome, which occur when 
drug use is deprived and disappear with the reintroduction of Δ9-THC [60], favor the recur-
rence of use by users attempting to stop. The main compounds that have activity on the can-
nabinoid receptor and mechanisms related to Cannabis withdrawal syndrome are as follows.
4.1. Agonist compounds
The involvement of the CB1 receptor with the development of dependence, as well as the 
expression of withdrawal symptoms, has already been evidenced in several animal experi-
ments. Therefore, it is suggested that treatment with low doses of CB1 receptor agonists 
could reduce the severity of withdrawal symptoms [61]. Low doses of Δ9-THC were tested 
to improve withdrawal symptoms; however, these doses exhibited reinforcing properties in 
chronic Cannabis users, eliminating THC as a viable treatment [62].
The endocannabinoids AEA and 2-AG, which are low and high efficiency agonists for the 
CB1 receptor, respectively, as well as fatty acid amide hydrolase (FAAH) enzymes responsible 
for the degradation of AEA and monoacylglycerol lipase (MAGL) responsible for the degra-
dation of 2-AG were proposed as mediating mechanisms of Cannabis withdrawal but lack 
further enlightening studies [6, 63].
4.1.1. Synthetic cannabinoids
These synthetic cannabinoid agonists present themselves as promising molecules, provid-
ing ample reduction in Cannabis withdrawal symptoms (mood, sleep, and food intake), both 
in the laboratory and in clinical settings. Unlike the isomer of THC and derived from the 
Cannabis plant, dronabinol, the synthetic cannabinoid nabilone (Figure 2) has potential to 
reduce self-administration of Cannabis, presenting as more promising for treatment [64].
Nabilone has more predictable side effects, and it is well tolerated among Cannabis users, 
better bioavailability, and longer duration of action than dronabinol, allowing the end of 
abstinence with a single daily dose [65]. In addition, nabilone produces non-Cannabis urinary 
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biomarkers that allow monitoring of abstinence through the use of standard urine toxicology 
during nabilone maintenance, but this consistently decreases Cannabis self-administration in 
the laboratory, ensuring that testing occurs in a clinical setting [66].
4.1.2. α2a adrenergic receptor agonist
Preclinical data have demonstrated that abstinence of cannabinoid is associated with adren-
ergic hyperactivity [67], and that α2 receptors agonists decrease the withdrawal symptoms of 
THC. Therefore, the α2a adrenergic receptor agonist, lofexidine (Figure 3), has been tested, and 
its use has improved sleep during the abstinence period and decreased Cannabis relapse [68] but 
is poorly tolerated even at less frequent doses and at lower target dose (0.6 mg three times a day), 
with 40% of patients presenting dizziness and fatigue [69]. Another α2-adrenergic agonist, guan-
facine hydrochloride (Figure 3), which improves memory performance in humans, was tested 
on the hypothesis that nocturnal administration of this drug would reduce Cannabis withdrawal 
while producing little evidence of sedation or hypotension. Daily administration of the compound 
significantly reduced irritability, produced small but significant decreases in blood pressure and 
heart rate, however was well tolerated, producing no sedation, dizziness, or altered food intake 
observed with lofexidine. Due to these results, guanfacine hydrochloride stands out as one of the 
first non-cannabinoid agonists to reduce cannabis abstinence-related irritability [64, 70].
Despite reductions in certain withdrawal symptoms, guanfacine did not reduce self-administration 
of Cannabis and did not worsen abstinence-related anorexia and weight loss but did not 
Figure 2. Chemical structure of isomer of THC, dronabinol and synthetic cannabinoid, and nabilone.
Figure 3. Chemical structure of α2a adrenergic receptor agonist.
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Figure 4. Chemical structure of nabiximols and terpenoids derived from C. sativa plants.
improve both. In contrast, lofexidine decreased self-administration of Cannabis in the labora-
tory after abstinence but worsened the performance of psychomotor tasks [68].
4.1.3. Nabiximols
Nabiximols are used to treat muscle spasticity associated with multiple sclerosis. These pro-
duce little intoxication, tolerance, or abstinence. They are oral spray medications containing 
THC, cannabidiol (CBD), and various terpenoids (Figure 4) derived from C. sativa plants. 
Once CBD attenuated the paranoia and euphoria associated with THC studies, nabiximols 
were used to treat Cannabis withdrawal and observed that they attenuated abstinence symp-
toms and improved patient compliance to treatment, as well as reducing irritability and 
depression of the users [71].
The indirect CBD agonist, which has a relatively low affinity for CB1 and CB2 receptors, inhibits 
AEA reuptake and hydrolysis while maintaining CB1 receptor stimulation, thus potentiating 
endocannabinoid transmission and emerging as an alternative treatment for the abstinence syn-
drome of C. sativa [72]. It is a compound with no significant adverse effects even with chronic 
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and high dose use. Due to this property on the endocannabinoid system, CBD has several phar-
macological effects, including anxiolytic, antipsychotic, neuroprotective, antiinflammatory, and 
antiemetic actions, favoring its use in the treatment of Cannabis withdrawal syndrome [73, 74].
Comparative studies of the use of nabiximols and dronabinol concluded that they did not 
produce significant cognitive or psychomotor adverse effects and showed a similar or lower 
reinforcement potential than dronabinol at lower doses [71, 75]. However, high doses of both 
drugs exhibited some potential for a booster. This fact highlights the need for careful monitor-
ing related to drug administration during future studies and clinical practice for treatment of 
dependence and abstinence from Cannabis with nabiximols.
4.2. Antagonists
The use of CB1 cannabinoid receptor antagonists is more related to the treatment of C. sativa 
dependence than to the treatment of withdrawal syndrome triggered by the withdrawal of 
this use in chronic users, as much as characteristic symptoms of withdrawal syndrome such 
as insomnia, dysphoria, and anxiety manifesting with the use of the CB1 receptor antagonist, 
rimonabant (also known as SR 141716A) (Figure 5) [8]. For this reason, the rimonabant, previ-
ously used in the treatment of obesity, was removed from the market in 2008, but it is useful 
in inducing signs of withdrawal in Cannabis-dependent individuals. One of the explanations 
is that the neural circuits involved with the serotonergic, noradrenergic, and dopaminergic 
systems have been shown to be sensitive to CB1 receptor antagonists [76, 77].
It is important to mention that the endogenous opioid system also contributes to the depen-
dence of Cannabis because it also has G protein-coupled membrane receptors [78], and users 
of opioid-dependent Cannabis are less likely to experience withdrawal symptoms. Opioid 
receptor antagonists, such as naltrexone, reduce self-administration of C. sativa and their sub-
jective positive effects in chronic plant users [79].
Figure 5. Chemical structure of SR 141716A.
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5. New studies on the treatment of withdrawal syndrome
There are no drugs approved for the treatment of addiction or withdrawal syndrome of Cannabis. 
Pharmacotherapy in these cases is focused exclusively on symptoms such as increased anxi-
ety, insomnia, loss of appetite, migraine, and irritability. We disclose these symptoms being 
a result of desensitization of CB1 receptors by THC studies advancing toward the develop-
ment of compounds that act selectively at this receptor. There are four main chemical classes 
of exogenous cannabinoid ligands under study: (a) classical cannabinoids such as Δ9-THC, 
AM2389, cannabinol, nabilone, HU-210, and other tricyclic terpenoid derivatives, such as 
Δ9-tetrahydrocannabivarin (Δ9-THCV) (Figure 6), which contains a polar benzopyran moiety 
attached to a hydrophilic (n-pentyl) alkyl terminus [80]; (b) the nonclassical cannabinoids CP 
55,940, HU-308 (Figure 7) and other bicyclic and tricyclic analogs of Δ9-THC without the 
pyran ring of classical cannabinoids [81]; (c) the aminoalkylindoles WIN55,212-2, JWH-018, 
JWH-073, and AM1241 (Figure 8), which differ in structure, lipophilicity, and binding activity 
at cannabinoid receptors compared to nonclassical cannabinoids [82]; and (d) biarylpyrazole 
ligands such as rimonabant and AM251 antagonists, which are selective for the CB1 receptor, 
and SR144528 (Figure 9), which is selective for the CB2 receptor [83].
5.1. In vivo and in vitro
It is known that because cannabinoid receptors, when bound by agonists or antagonists, have 
the potential to treat a variety of pathologies such as pain, neurodegeneration, obesity, tumors, 
Figure 6. Chemical structure of classical cannabinoids.
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chemical dependency, and immune function, it is important to develop in vitro bioassays activ-
ity determination and the function of these receptors [84]. The in vitro assays established in the 
studies related to CB1 and CB2 receptors involve the use of membranes or tissues containing 
Figure 7. Chemical structure of the non-classical cannabinoids.
Figure 8. Chemical structure of the aminoalkylindoles.
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these receptors [85]. Of particular note is the assay using radiolabeled CB1 or CB2 receptors with 
[3H] CP55940 (Figure 10) and bioassays with preparations of nerve-smooth muscle where the 
ability of the molecule under study to produce inhibition or excitation of cannabinoid receptors 
is verified [86].
In vitro functional bioassays measure the effects of synthetic cannabinoids and their metabo-
lites in relation to cannabinoid receptor signaling CB1/CB2, evaluating the production of 
cyclic ATP and elevation of intracellular calcium. In the middle of the last century, initial 
studies on the effects of cannabinoids used Gayer’s tests (found at the time as a useful test for 
the effects of THC [87]), where corneal areflexia was measured in rabbits, catatonia in mice, 
and increased defecation and aggressiveness in rats stressed by REM sleep deprivation [88]. 
In mice, high-dose catalepsy with Δ9-THC was also observed [95]. In rodents, the main bioas-
say is the measurement of locomotor activity, rectal temperature, and analgesia (in the tail or 
hot plate test) [89].
The sum of the various symptoms observed in the initial studies originated characteristic 
effects in laboratory animals called cannabinoid tetrad and being characterized by hypother-
mia, analgesia, catalepsy, and locomotor suppression [90]. This tetrad is widely used nowa-
days because, since the data obtained through its observation are qualitatively consistent, it is 
common to evaluate the dose-dependence relation of cannabinoids quickly and without any 
specific training of the animals, a fact that is configured as an advantage [89].
The Δ9-THC dependency/withdrawal modeling studies are based on the cannabinoid tetrad 
in which The triggered effects are verified with the administration of cannabinoid antagonist 
(usually rimonabant), and precipitation withdrawal symptoms, being, in general, the syn-
thetic cannabinoids such as UR-144 (Figure 11), responsible to promote effects greater than 
that of Δ9-THC [91].
Studies in rats revealed that individual enzyme activity mainly related to the genetic polymor-
phisms of cytochrome P450 enzymes in the phase I metabolism of cannabinoids has an impor-
tant role in determining the response of an individual on the use of cannabinoids [92]. Thus, 
an individual may experience attenuated effects and other individual effects exacerbated by 
Figure 9. Chemical structure of the biarylpyrazole ligands such as rimonabant and AM251 antagonists.
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cannabinoids, depending on the liver enzyme profile that favors the formation of antagonistic 
or agonist metabolites, respectively [93].
Technological refinement has led to the use of new techniques and different experimental 
models [94] in the studies of compounds in potential for reinforcement, with the search for 
Figure 10. Chemical structure of the CP55940.
Figure 11. Chemical structure UR-144.
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new targets and biomarkers [95]. Among the experimental models emerges the Danio rerio 
(Zebrafish), a small fish, because it has the facility of genetic manipulation and the biology 
of its development [96]. Zebrafish is particularly useful for measuring changes in the devel-
opment of the nervous system [97], and its measures of sensorimotor plasticity, emotional 
function, cognition, and social interaction have been used to characterize the adverse effects 
of drug abuse such as Δ9-THC [98, 99] due to phylogenetic analyzes, which reveal the endo-
cannabinoid system as highly conserved between Zebrafish and mammals [100].
Tolerance and cross-tolerance tests for cannabinoids are also performed in vivo, although 
studies indicate that not all effects of cannabinoids are developed during these tests, for 
example, adrenocorticotropic hormone (ACTH) secretion is not observed in rodents during 
these tests, indicating low reliability and the need for greater improvement in vivo methods 
used in this sense [101, 102].
5.2. In silico
There are several computational methods; among them, homology modeling is being used 
in cannabinoid studies [103], considering that the drugs utilized during the withdrawal syn-
drome of C. sativa act at a symptomatic level. The resolution of the crystalline structure of 
the CB1cannabinoid receptor is recent [19], and this fact favored in silico studies that evolve 
toward the planning of molecules that act as selective agonists of this receptor, mainly stud-
ies related to better understanding of the interaction and the relation structure-activity of 
Figure 12. Chemical structure of Stemphol.
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synthetic cannabinoids [104]. A study can be mentioned where computational tools were 
used, with the objective of proposing drug candidates for the treatment of the abstinence 
syndrome based on the natural ligands of this receptor. A particular compound derived from 
marine fungi, stemphol (Figure 12) [105], presented positive predictions regarding pharma-
cokinetic and toxicological properties for a human CB1 receptor ligand, in addition to having 
a relatively simple molecular structure. Due to these computational results and the recent 
crystallographic elucidation of the cannabinoid CB1 receptor [20], experimental studies are 
being conducted for the development of candidate pharmacotherapeutic alternatives for the 
treatment of C. sativa withdrawal syndrome [106].
6. Conclusion
Studies on cannabinoids were stimulated after the characterization and structural elucidation 
of Δ9-THC in the 1960s, and later on, the discovery of the cannabinoid system represented 
by CB1/CB2 receptors and binding substances to these receptors. Many in vitro, in vivo, and 
in silico trials have been developed in the last decades, and advances mainly regarding the 
mechanism of addiction, abuse, and withdrawal syndrome have been achieved. However, 
with the use of cannabinoid-based drugs and the chemical development of synthetic cannabi-
noids, further studies into these mechanisms are relevant, especially considering that Δ9-THC 
is a low-efficacy cannabinoid compared to the “new cannabinoids.”
It is expected in the future that the investigations will deepen the knowledge on the mechanisms 
of the cannabinoids, especially those that cause chemical dependence, both as cannabinoid 
system and as noncanabinoid physiological systems. In this way, it is possible to increase the 
knowledge about the different classes of these substances and, therefore, favor the development 
of new models and improvement of the tests currently used in the studies related to C. sativa.
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